免疫检查点调节光敏感剂,针对BRD4进行癌症光免疫疗法
Peixia Li1, Yayin Du1, Jingru Qiu1
1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province 250012, P. R. China.
Journal of medicinal chemistry
|October 24, 2024
概括
一种针对BRD4的新型光敏感剂BRD-PS通过诱导细胞死亡和降低PD-L1.1的调节,将冷瘤转化为热瘤. 这种方法增强了细胞毒性T淋巴细胞的透,用于有效的癌症光免疫疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 摄影化学的使用.
背景情况:
- 光动力疗法 (PDT) 可以通过诱导免疫细胞死亡 (ICD) 来增强抗瘤免疫力.
- 瘤通常通过过度表达像PD-L1.1这样的免疫检查点来逃避免疫监测.
- 克服免疫逃避对于有效的癌症免疫疗法至关重要.
研究的目的:
- 设计一种新的光敏剂,可以同时诱导ICD并克服免疫逃避.
- 开发一种针对BRD4的光敏感剂 (BRD-PS) 作为免疫检查点调节剂.
主要方法:
- 设计和合成BRD-PS,一个针对BRD4的光敏感剂.
- 评估BRD-PS诱导热和铁 (ICD类型) 的能力.
- 评估BRD-PS对PD-L1表达和瘤中T细胞透的影响.
主要成果:
- BRD-PS有效诱导了免疫性热和铁,促进了细胞毒性T细胞的激活和透.
- BRD-PS抑制了PD-L1的表达,减轻了免疫逃避.
- 这项研究证明了癌症光免疫疗法的协同效应.
结论:
- BRD-PS代表了一类新的免疫检查点调节光敏剂.
- 同时诱导ICD和PD-L1下调通过单个药物是可行的.
- 这一策略对协同的癌症光免疫疗法具有前景.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


